Sigilon Therapeutics, Inc.

Sigilon Therapeutics, Inc.

Sigilon Therapeutics, Inc.

Overview
Date Founded

2015

Headquarters

100 Binney Street, Suite 600, Cambridge, MA, 02142, USA

Type of Company

Public

Employees (Worldwide)

11 - 50

Industries

Biotechnology

Company Description

Sigilon Therapeutics, Inc. engages in the research and development of therapeutic treatments for a wide range of chronic diseases. The company was founded by Daniel G. Anderson, Robert S. Langer Jr., Jose Oberholzer, Arturo Vegas, and Omid Veiseh on May 14, 2015 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Sigilon Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Co-Founder

Co-Founder

Co-Founder

Co-Founder

President & Chief Executive Officer

Chief Financial Officer

Chief Operating Officer

Chief Technology Officer

Secretary & Chief Legal Officer

Board of Directors

Managing Partner at Flagship Pioneering

Venture Partner of Cathay Health at Cathay Capital Private Equity SAS (China)

President & Chief Executive Officer at Seres Therapeutics, Inc.

Chief Executive Officer at Repertoire Immune Medicines

Co-Founder at Sigilon Therapeutics, Inc.

Former Venture Partner at New Enterprise Associates

President & Chief Executive Officer at Sigilon Therapeutics, Inc.

Director at X-Vax Technology, Inc.

Senior Partner at Flagship Pioneering

Paths to Sigilon Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Sigilon Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Flagship Pioneering seeks investment opportunities in companies located globally. The firm focuses on companies operating in the fields of therapeutics, life science tools & diagnostics, and bioenergy or cleantech. It provides financing for seed, early, and later-stage capital requirements. It acts as a lead investor. It also makes co-investments.

Details Hidden

Avidity Partners Management LP (APM) is a hedge fund manager headquartered in Dallas, Texas founded by Michael David Gregory. APM provides investment advice.

Details Hidden

HarbourVest invests in companies across global primarily in US, China and Japan. The firm targets companies operating across a broad range of sectors. They provide financing for buyout, growth equity, mezzanine and direct co-investments.

Recent Transactions
Details Hidden

Sigilon Therapeutics, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Transaction Advisors
Underwriter

Advised onSigilon Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onSigilon Therapeutics, Inc. issued USD Common Stock

Escrow Agent

Advised onSigilon Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Advisor

Chief Executive Officer, President & Director at Obsidian Therapeutics, Inc.

Advisor
Clients

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Key Stats and Financials As of 2019
Market Capitalization
$1.13B
Total Enterprise Value
Earnings Per Share
$-1.41
Revenue
$14.2M
Net Profit
$-43.9M
EBITDA
$-43.4M
EBITDAMargin
-306.95%
Total Debt
$115M
Total Equity
$-77.8M
Investors
Details Hidden

Flagship Pioneering seeks investment opportunities in companies located globally. The firm focuses on companies operating in the fields of therapeutics, life science tools & diagnostics, and bioenergy or cleantech. It provides financing for seed, early, and later-stage capital requirements. It acts as a lead investor. It also makes co-investments.

Details Hidden

The Vanguard Group is an American investment management company based in Malvern, Pennsylvania, that manages approximately $3.4 trillion[1] in assets. It is the largest provider of mutual funds and now the second-largest provider of exchange-traded funds (ETFs) in the world after BlackRock, with about $451 billion in ETF assets under management, as of March 2015.[3] It offers mutual funds and other financial products and services to retail and institutional investors in the United States and abroad. Founder and former chairman John C. Bogle is credited with the creation of the first index fund available to individual investors,[4] the popularization of index funds generally,[5] and driving costs down across the mutual fund industry.

Details Hidden

Managing Partner at Flagship Pioneering

Suppliers
Massachusetts Institute of Technology Hospitals & Patient Services | Cambridge, MA

Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts, United States. MIT has five schools and one college, containing a total of 32 academic departments, with a strong emphasis on scientific, engineering, and technological education and research. Founded in 1861 in response to the increasing industrialization of the United States, the institute used a polytechnic university model and stressed laboratory instruction. MIT was elected to the Association of American Universities in 1934.

Competitors
Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

CRISPR Therapeutics AG Biotechnology - Zug, Che

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Sigilon Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Sigilon Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Sigilon Therapeutics, Inc..